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ATM
Chk2High expression of Aurora kinase A (Aurora-A) has been found to confer cancer cell radio- and chemoresistance,
however, the underlying mechanism is unclear. In this study, by using Aurora-A cDNA/shRNA or the speciﬁc in-
hibitor VX680, we show that Aurora-A upregulates cell proliferation, cell cycle progression, and anchorage-
independent growth to enhance cell resistance to cisplatin and X-ray irradiation through dysregulation of DNA
damage repair networks. Mechanistic studies showed that Aurora-A promoted the expression of ATM/Chk2,
but suppressed the expression of BRCA1/2, ATR/Chk1, p53, pp53 (Ser15), H2AX, γH2AX (Ser319), and RAD51.
Aurora-A inhibited the focus formation of γH2AX in response to ionizing irradiation. Treatment of cells overex-
pressing Aurora-A and ATM/Chk2 with the ATM speciﬁc inhibitor KU-55933 increased the cell sensitivity to cis-
platin and irradiation through increasing the phosphorylation of p53 at Ser15 and inhibiting the expression of
Chk2, γH2AX (Ser319), and RAD51. Further study revealed that BRCA1/2 counteracted the function of Aurora-
A to suppress the expression of ATM/Chk2, but to activate the expression of ATR/Chk1, pp53, γH2AX, and
RAD51, leading to the enhanced cell sensitivity to irradiation and cisplatin, which was also supported by the re-
sults from animal assays. Thus, our data provide strong evidences that Aurora-A and BRCA1/2 inversely control
the sensitivity of cancer cells to radio- and chemotherapy through the ATM/Chk2-mediated DNA repair net-
works, indicating that the DNA repairmolecules including ATM/Chk2may be considered for the targeted therapy
against cancers with overexpression of Aurora-A.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Radio- and chemotherapy are two principal approachesmostly used
to destroy cancer cells through inducing irreparable DNA damage [1].
However, the acquired resistance of cancer cells to ionizing radiation
(IR) or chemotherapy is themajor obstacle to improving cancer patient
survival. The serine/threonine kinase Aurora-A, namely Aurora kinase A
(AURKA), breast tumor activated kinase (BTAK), or serine threonine
kinase 15 (STK15), is a member of the Aurora kinase family reported
to induce centrosome ampliﬁcation, chromosomal instability and trans-
formation in mammalian cells [2]. However, the function of Aurora-A
has not been fully explored in cancer cells. Over the past several years,
increasing evidences have shown that overexpression of Aurora-A is
associated with radio- and chemoresistance. For instances, theur-Ai, Aurora-A shRNA-infected
CA2 shRNA-infected cells; Scr,
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ights reserved.ampliﬁcation of Aurora-A increases radioresistance in laryngeal cancer
cells [3], and Aurora-A may lead to cervical cancer radioresistance
through enhancing the transcription activity of NF-κB [4]. In esophageal
squamous cell carcinoma (ESCC) cells, overexpression of Aurora-A in-
hibits the cisplatin- or UV irradiation-induced apoptosis, but silencing
of the endogenous Aurora-A kinase with siRNA substantially enhances
the sensitivity to cisplatin or UV [5]. In patients with epithelial ovarian
cancer, overexpression of Aurora-A is correlated with the resistance to
carboplatin and indicates a poor prognosis [6]. Silencing of Aurora-A in-
creases the colorectal cancer stemcell sensitivity to 5-FU and oxaliplatin
[7]. The abnormal expression of Aurora-A is involved in chemoresistance
through ZNF217 in breast cancer cells [8]. In a recent study, Aurora-A
was proven to play a critical role in the acquired chemoresistance of
chronicmyelogenous leukemia cells to the tyrosine kinase inhibitor ima-
tinib [9]. But the mechanism that Aurora-A induces radio- and
chemoresistance is not clear.
ATM-Chk2 (Ataxia telangiectasia mutated kinase/the checkpoint
kinase 2) and ATR-Chk1 (Ataxia telangiectasia and Rad3-related
protein/the checkpoint kinase 1) are two major branches at the up-
stream of the DNA damage repair signaling [10], and the active ATM
usually phosphorylates the histone H2AX at Ser139, yielding γH2AX
to trigger DSB repair [11]. Breast cancer type 1/2 susceptibility proteins
(BRCA1/2), two tumor suppressors, also function to participate in DNA
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teins usually perform their functions to repair DNA lesions induced by IR
or genotoxic agents, while in cancer cells, mutation or inactivation of
BRCA1/2 often causes DNA repair deﬁciency, resulting in increased
radio- and chemosensitivity. However, most of the recurrent or meta-
static cancer cells are featuredwith the acquired resistance to treatment
with IR and genotoxic agents due to the dysregulation of DNA repair
networks associated with BRCA1/2 and ATM/Chk2 [13,14].
Themounting evidences have suggested that Aurora-Amay regulate
BRCA1/2 and the other DNA repair proteins. Aurora-A physically binds
to and phosphorylates BRCA1 at Ser308, leading to the abrogation of
G2/M checkpoint [15]. In ovarian cancer cells, Aurora-A represses
BRCA2 expression, while silencing of Aurora-A restores the level of
BRCA2, and increases the number of the DNA repair foci of both
BRCA2 and Rad51 after γ-irradiation [16]. Sourisseau et al. reported
that, in normal mammary cells, overexpression of Aurora-A modulates
the activity of the checkpoint kinase 1 (Chk1) and inhibits RAD51
recruitment to DNAdouble strand-breaks (DSBs) induced by X-ray irra-
diation [17]. They also found that the decreased DSB repair sensitizes
cancer cells to PARP inhibition, which requires the inhibition of Chk1
by the Polo-like kinase 1 (PLK1), and that in pancreatic cancer cells, ec-
topic expression of Aurora-A inhibits the homologous recombination
(HR) in cells with the wide-type BRCA2, but has no such effect in cells
with the mutant BRCA2 [17].
In the present study, we used breast, pancreatic, and ovarian cancer
cells to investigate the function of Aurora-A in radio- and
chemoresistance. Our results indicate that Aurora-A and BRCA1/2 are
mutually suppressed to control cell sensitivity to radio- and chemother-
apy mainly through the ATM/Chk2-mediated DNA repair networks as-
sociated with p53, pp53, γH2AX, and RAD51.
2. Materials and methods
2.1. Cell lines and cell culture
Human breast cancer cell lines (MCF-7 and MDA-MB-231), pan-
creatic cancer cell lines (PANC-1 and BXPC3), ovarian epithelial can-
cer cell lines (OVCA420 and OVCA429), and retroviral packaging
cells (Phoenix amphotropic cells) were purchased from American
Type Culture Collection (ATCC, US). MCF-7, PANC-1 and Phoenix
were maintained in Dulbecco's modiﬁed Eagle's medium (DMEM,
Gibco). MDA-MB-231, BXPC3, OVCA420 and OVCA429 were main-
tained in Roswell Park Memorial Institute (RPMI) 1640 medium.
Both the cell culture media were supplemented with 10% fetal bo-
vine serum, 2 mM L-glutamine, penicillin (100 units/ml), and strep-
tomycin (100 μg/ml). All cells were incubated at 37 °C in an
atmosphere of 5% CO2 and 95% air.
2.2. Plasmid construction and cell transfection or viral infection
To enhance the expression of Aurora-A, BRCA1, and BRCA2, human
wide type cDNAs of Aurora-A, BRCA1 and BRCA2 were inserted into
pBabe/puromycin, pcDNA3.1-neomycin, or pCIN-neomycin, respec-
tively. Viruses from pBabe vectors were produced and used to infect
MCF-7, PANC-1 and OVCA420 cells, and to generate Aurora-A overex-
pression cell lines: MCF-7/Aur-A, PANC-1/Aur-A, and OVCA420/Aur-A
using the previously published methods [16]. The control cell lines
were generated by infection of the same cell lines with viruses contain-
ing empty vectors. pcDNA3.1 and pCIN vectors contain BRCA1 and
BRCA2 cDNAs were transfected into MDA-MB-231, BXPC3 and
OVCA429 by Fugene 6 (Roche) according to the manufacturer's in-
structions, to generate BRCA1 or BRCA2 overexpression cell lines:
MDA-MB-231/BRCA1, MDA-MB-231/BRCA2, BXPC3/BRCA1, BXPC3/
BRCA2, OVCA429/BRCA1, OVCA429/BRCA2, and OVCA420/Aur-A/
BRCA1, OVCA420/Aur-A/BRCA2. Cells transfected with vectors wereused as controls. The resulting cells were selected with puromycin
(1.5–2.0 μg/ml) or neomycin (0.5–2.5 mg/ml) for 7–14 days.
To silence the expression of Aurora-A, BRCA1 and BRCA2, the DNA
oligonucleotides used to generate shRNA against the open reading
frame of mRNA were 5′-GUCUUGUGUCCUUCAAAUU-3′(Aurora-A
shRNA), 5′-AAGUACGAGAUUUAGUCCG-3′ (BRCA1 shRNA) and 5′-
ACAAUUACGAACCAAACCG-3′ (BRCA2 shRNA). pBabe/U6-puromycin-
Aurora-Ai, pBabe/U6-neomycin-BRCA1i and pBabe/U6-neomycin-
BRCA2i were generated according to the previously reported method
[16]. The control vectors were similarly constructed by directly
inserting a scrambled shRNA (Scr) into pBabe/U6-neomycin [16]. Ret-
roviral particles were generated by using the same method mentioned
above, and were used to infect and generate new cell lines including
MDA-MB-231/Aur-Ai, BXPC3/Aur-Ai, and OVCA429/Aur-Ai cell lines,
and MCF-7/BRCA1i, MCF-7/BRCA2i, PANC-1/BRCA1i, PANC-1/BRCA2i,
OVCA420/BRCA1i, OVCA420/BRCA2i, and OVCA429/Aur-Ai/BRCA1i,
OVCA429/Aur-Ai/BRCA2i. Corresponding control cells expressing scram-
bled shRNAwere labeled as Scr. The infected cellswere selectedwith pu-
romycin (1.5–2.0 μg/ml) or neomycin (0.5–2.5 mg/ml) for 7–14 days.
2.3. Cell proliferation and anchorage-independent colony
To test cell proliferation, 5 × 103 cells (5 × 104 cells of BXPC3) were
seeded into 12-well plates (each cell line in 15 wells) and incubated at
37 °C in an atmosphere of 5% CO2 and 95% air and counted from 3
wells every 2 days individually for a total of 8 days (4 counts). The num-
ber of cells was recorded. The assay was repeated three times in
duplicate.
For anchorage-independent colony formation, 5 × 103 cells of each
cell line were suspended in 1 ml of medium with 0.35% agarose (Life
Technologies, US), and the suspension was placed on top of 4 ml of
solidiﬁed 0.7% agarose. Triplicate cultures of each cell type were main-
tained at 37 °C in a 5% CO2 atmosphere, and the fresh medium was fed
once a week. The number of colonies N50 μm (~100 cells, for MCF-7,
PANC-1 and OVCA420 cell lines), or N30 μm (~50 cells, for MDA-MB-
231, BXPC3 andOVCA429 cell lines) in diameter in each dishwas count-
ed at 14 to 21 days. The assay was repeated at least three times in
duplicate.
2.4. Chemical compounds and X-ray irradiation
The Aurora kinase inhibitor VX680 and the ATM inhibitor KU-55933
were purchased from Selleck Company (Texas, US), and cisplatin were
purchased from QiLu pharmaceutical company (Shandong, China) and
dissolved in DMSO. The ﬁnal concentration of VX680 was 0.6 nM,
which speciﬁcally inhibits the activity of Aurora-A according to the
manufacturer's instructions, while KU-55933 was 13 nM. The ﬁnal con-
centration of cisplatinwas determined for different cell lines and the ex-
perimental purpose. The ﬁnal concentration of DMSO as diluent in cell
culture used throughout the study did not exceed 0.1%.
For X-ray irradiation, 1–3 × 106 cells were seeded into 6-well plates
and incubated at 37 °C. When the cell density reached 80%, the cells
were exposed to X-ray irradiation at 8 Gy as pretested and harvested
for apoptosis analysis 3 days later (4 days for OVCA420 and its
derivatives).
2.5. The half-maximal inhibitory concentration
The half-maximal inhibitory concentration (IC50) was measured
by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide
(MTT) assay. Cells were seeded in 96-well plates at a density of
8000 cells/well in 100 μl of medium (DMEM/RPMI 1640). After over-
night incubation at 37 °C, cisplatin at a series of concentrations was
added to each well. After treatment with cisplatin for 48 h, 20 μl of
0.5 mg/ml MTT mixed with 180 μl medium was added to each well
for incubation of 4 h, followed by 150 μl of DMSO for 10 min. Data
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subtracted from the background OD at 490 nm. IC50 was calculated
by the algebraic formula of the improved Karber method (lgIC50 =
Xm-I[P-(3-Pm-Pn)/4]; Xm: lg (maximum dose), I: lg (maximum
dose / adjacent dose), P: sum of the positive reaction rates, Pm:
maximum positive reaction rate, Pn: minimum positive reaction
rate). The experiment was repeated three times in triplicate.
2.6. Cell cycle and apoptosis analysis
Cell cycle and apoptosis were analyzed through ﬂow cytometry
(FAC Station; BD Biosciences, US) using the previously described
protocols [18]. Propidium iodide and RNase were purchased from
Sigma-Aldrich (Missouri, US); Annexin V-ﬂuorescence apoptosis
detection kit I was acquired from BD Biosciences PharMingen. The
assay was repeated three times.
2.7. Immunoblotting analysis
To analyze protein expression in cells, immunoblotting was
performed as previously described [18]. Antibodies against theFig. 1. Expression of Aurora-A and effects of Aurora-A on cell cycle progression and an
expression. β-actin was used as a loading control. The intensity of protein bands was a
graph is shown in SFig. 7A. B. Quantitative analysis of cell cycle distribution. The cell cycle d
iodide. C. Anchorage independent growth in soft agar. The colony formation rate of cont
**Pb0.01. Data were collected from three independent experiments.following proteins were obtained from Cell Signaling Technology
(Massachusetts, US): Aurora-A, H2AX, ATR, ATM, Chk1, Chk2,
pp53 (Ser15). Antibodies against the following proteins were
obtained from Santa Cruz Technology (California, US): p53,
BRCA1, BRCA2, RAD51. The antibodies against γH2AX (Ser139)
and β-actin were purchased from Biolegend and Sigma-Aldrich
companies, respectively. The secondary antibodies were F(ab)2
fragment of donkey anti-mouse immunoglobulin or of donkey
anti-rabbit immunoglobulin linked to horseradish peroxidase
from Amersham Biosciences (Buckinghamshire, UK). Immunoblot
reagents were from an electrochemiluminescence kit (Amersham
Biosciences). The intensity of protein bands was quantiﬁed with
Image J software downloaded from NIH website (http://imagej.
nih.gov/ij/).
2.8. Immunoﬂuorescence
Immunoﬂuorescence staining was performed according to a pub-
lished protocol [16]. DNA dye DAPI and primary antibodies against
Aurora-A and γH2AX (Ser139) were obtained from Molecular Probes,
Cell Signaling Technology and Biolegend. The secondary antibodieschorage-independent colony formation. A. Immunoblotting analysis of Aurora-A
nalyzed by Image J software and labeled under each band, and the intensity-based
istributionwas determined by ﬂow cytometry after cells were stainedwith propidium
rol cell lines was set at 100%. Error bars = 95% conﬁdence intervals (CIs). *P b 0.05,
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against mouse IgG or rabbit IgG (Jackson ImmunoResearch Laboratory).
For DNA damage foci examination, cells were ﬁrst treatedwith X-ray ir-
radiation (8 Gy), then incubated for 6 h before immunoﬂuorescence
staining. All stained cells were examined and photographed with a
Leica SP5 confocal ﬂuorescence microscope.Fig. 2. Cell sensitivity to X-ray irradiation and cisplatin. A and C. Percentage of early apoptotic ce
bars = 95% CIs; E and H. Values of half-maximal inhibitory concentration (IC50) of cisplatin. Ce
80 mg/L) for 48 h. IC50was calculated according to themethod described inMaterials andmet
centage of late apoptotic cells. Cells were treatedwith 10 mg/L (5 mg/L for BXPC3-Scr, and BXP
ﬂow cytometry in cells stained with annexin V and propidium iodide. Error bars = 95% CIs.2.9. Xenograft tumors in nude mice
To detect the in vivo effects of Aurora-A on chemo- and radio-
resistance, we selected the series of MDA-MB-231 cells to generate
xenograft mouse tumor model. Brieﬂy, 5 × 106 cells of MDA-MB-231/
Scr, MDA-MB-231/vector, MDA-MB-231/Aur-Ai, MDA-MB-231/BRCA1,lls to X-ray irradiation. B and D. Percentage of late apoptotic cells to X-ray irradiation. Error
lls (as indicated) were treated with cisplatin at different concentrations (2.5, 5, 10, 20, 40,
hods section. Error bars= 95% CIs. F and I. Percentage of early apoptotic cells. G and J. Per-
C3-Aur-Ai) cisplatin or cisplatin plus VX680 (0.6 nM) for 48 h. Apoptosis wasmeasured by
Fig. 3.DNA damage repair networks regulated by Aurora-A. A. Aurora-A upregulated ATM/Chk2, but downregulated ATR/Chk1. B. Detection of the altered expressions of p53, pp53, H2AX,
γH2AX, and RAD51 in cells expressing Aurora-A cDNA or shRNA aswell as in their control cells. β-actinwas used as a loading control. The intensity of protein bands is labeled under each
band, and the intensity-based graphs are shown in SFig. 7B–C. C. Quantitative analysis of the number of foci formed by γH2AX from 1000 cells in randomly selected 10microscopic views
from 5 slides (P b 0.05). High expression of Aurora-A decreased the number of foci, while silencing of Aurora-A increased the focus formation of γH2AX. The focus formation assay and the
quantiﬁcation of foci were repeated ﬁve times by using cells at different passages.
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6-week-old BALB/c athymic nude mice (Department of Laboratory
Animals, Fudan University). The animal experiments were approved
by the Institutional Animal Care and Use Committee of Fudan
University and performed following Institutional Guidelines and
Protocols. Each cell line was bilaterally injected into 18 mice, for a
total of 36 injections. The longest diameter “a” and the shortest
diameter “b” of tumors were measured and the tumor volume was
calculated with the use of the following formula: tumor volume
(in mm3) = a × b2 × 0.52 [17], where 0.52 is a constant to calculate
the volume of an ellipsoid. When the volume of tumors reached
1.0 cm in diameter (around 38 days post injection), the mice injected
with each cell line were randomly divided into 3 subgroups: control
group, X-ray group and cisplatin group, 6 mice for each subgroup.
The mice in X-ray group were exposed to 10 Gy X-ray once every
6 days for a total of three exposures, while the mice in cisplatin
group were injected intraperitoneally with 0.05 mg cisplatin per
gram of body weight once every 6 days for a total of three times.
The control groups were either irradiated with 0 Gy (for MDA-MB-
231/vector cells) or treated with DMSO (for MDA-MB-231/Scr cells).When the biggest tumor in control and diluent groups reached 2.0 cm
in diameter, all experimented mice were sacriﬁced simultaneously and
the tumor size was measured accordingly.
2.10. Statistical analysis
The Student t test was used for statistical analysis of all data. P b 0.05
was considered signiﬁcant.
3. Results
3.1. Aurora-A promotes the cell proliferation, cell cycle progression and
anchorage-independent growth
To investigate the roles of Aurora-A in radio- and chemoresistance,
we delivered cDNA or shRNA of Aurora-A into breast, pancreatic, and
ovarian cancer cell lines that were pretested with low or high expres-
sion of Aurora-A, and ﬁrst characterized the proliferation, cell cycle pro-
gression, and anchorage independent growth of resulting cell lines. The
results fromWestern blotting showed that Aurora-Awas overexpressed
Fig. 4. Inhibition of ATM reverses the radio- and chemoresistance in cells overexpressing
Aurora-A. A. Representative graphs showing the percentage of apoptotic cells tested by
ﬂow cytometry after treatment with KU-55933 plus IR or cisplatin. The late apoptosis of
cells with double staining of PI and FITC is indicated in ﬁrst quadrant, while the early
apoptosis with single staining of FITC is indicated in the fourth quadrant. B. Quantitative
analysis of cell apoptosis from ﬁve repeated tests by ﬂow cytometry. C. Changes of DNA
damage repair associated proteins in cells treated with IR or cisplatin. The intensity of
protein bands is labeled under each band, and the intensity-based graph is shown in
SFig. 7D. D. The effects of ATM inhibition on DNA damage repair proteins tested by
Western blot. β-actin was used as a loading control. The intensity of protein bands is la-
beled under each band, and the intensity-based graph is shown in SFig. 7E.
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silenced in MDA-MB-231/Aur-Ai, BXPC3/Aur-Ai, and OVCA429/Aur-Ai
cells compared with in control cells (Fig. 1A). The intensity of protein
bands was analyzed by Image J software and labeled under each band,and the intensity-based graph is shown in SFig. 7A. Overexpression of
Aurora-A promoted cell proliferation, but knockdown of Aurora-A
restrained cell growth (SFig. 1).
Compared with the control cells, the cell population in S phase was
increased by 7.8%, 5.5%, and 4.4%, but that in G0–G1 phase was
decreased by 1.7%, 7.2%, and 10.9%, respectively in MCF-7/Aur-A,
PANC-1/Aur-A, and OVCA420/Aur-A cells. The number of cells in
G2–M phase was inconsistently altered. Silencing of Aurora-A in
MDA-MB-231, BXPC3, and OVCA429 cells reduced the number of S
phase cells by 4.5%, 39.2%, and 3.8%, but increased the number of
cells in G0–G1 phase by 23.2%, 13.7%, and 6.2%, respectively. The
population in G2–M phase was decreased by 18.8% and 2.3% in
MDA-MB-231/Aur-Ai and OVCA429/Aur-Ai, but was increased in
BXPC3/Aur-Ai (Fig. 1B). These data suggest that Aurora-A functions
to stimulate overall cell cycle progression mainly through G1–S tran-
sition, which is consistent with our recent report tested in different
cell lines [19].
The results from soft agar assay showed that the number of
colonies was twice more in PANC-1/Aur-A cells than in PANC-1/
vector cells, and the colonies formed by BXPC3/Aur-Ai cells were
much fewer than those by BXPC3/Scr cells. Similarly, compared
with the corresponding control cells, the number of colonies was
increased by 45.2% and 68.6% in MCF-7/Aur-A and OVCA420/Aur-A,
but was decreased by 39.1% and 25.3% in MDA-MB-231/Aur-Ai and
OVCA429/Aur-Ai (Fig. 1C).
The above results suggested that the ampliﬁcation of Aurora-A
promoted the cancer cell proliferation, cell cycle progression, and
in vitro tumorigenicity.
3.2. Overexpression of Aurora-A confers cancer cell resistance to X-ray
irradiation and cisplatin treatment
To evaluate the effect of Aurora-A on cell sensitivity to ionizing
radiation (IR), cells were exposed to X-ray (8 Gy) and detected for
early and late apoptosis by ﬂow cytometry. As shown in Fig. 2 and
SFig. 2A, in response to irradiation, the proportion of early apopto-
tic cells was reduced by 0.7%, 13.5%, and 0.2% (Fig. 2A), and the pro-
portion of late apoptotic cells was reduced by 15.3%, 8.9%, and 7.3%
in MCF-7/Aur-A, PANC-1/Aur-A, and OVCA420/Aur-A cells, respec-
tively, compared with in vector-transfected control cells (Fig. 2B).
Knockdown of Aurora-A increased the early apoptotic cells by
about two and ten folds in BXPC3/Aur-Ai and OVCA429/Aur-Ai
cells, but no difference of early apoptosis was seen in MDA-MB-231
cells before and after Aurora-A was silenced (Fig. 2C). Compared
with the control cells, the late apoptotic cells were increased by
one fold at least in BXPC3/Aur-Ai, OVCA429/Aur-Ai, and MDA-MB-231/
Aur-Ai cells (Fig. 2D). These data suggested that overexpression of
Aurora-A restrained both the early and late apoptosis of cancer cells to ra-
diation treatment, leading to the reduced radiosensitivity.
Next, we tested whether Aurora-A was associated with
chemoresistance. As shown in Fig. 2E, compared with the
corresponding control cells, the half maximal inhibitory concentra-
tion (IC50) of cisplatin was increased by 4.4%, 12.4%, and 4.4% in
MCF-7/Aur-A, PANC-1/Aur-A, and OVCA420/Aur-A cells, respec-
tively. The number of early apoptotic cells was reduced by 1.3%,
4.7% and 0.1%, respectively, in MCF-7/Aur-A, PANC-1/Aur-A, and
OVCA420/Aur-A cells, while the late apoptotic cells were decreased
by 6.5%, 8.5% and 9.0%, respectively, in cells overexpressing Aurora-
A (Fig. 2F–G and SFig. 2B).
Since VX680, a small compound, was reported to selectively inhibit
the activity of Aurora kinase, we used the chemical at the concentration
(0.6 nM) to speciﬁcally inhibit the activity of Aurora-A as reported
elsewhere [20], to test whether the inactivation of Aurora-A by VX680
was able to increase cell apoptosis to chemotherapeutic treatment.
Concurrent treatment of MCF-7/Aur-A, PANC-1/Aur-A, and OVCA420/
Aur-A cells with VX680 and cisplatin induced the number of both
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alone (Fig. 2F–G and SFig. 3 upper panel).
On the other hand, silencing of Aurora-A decreased the IC50s and
increased apoptosis in MDA-MB-231/Aur-Ai, BXPC3/Aur-Ai, and
OVCA429/Aur-Ai cells, compared with the control cells (Fig. 2H–J
and SFig. 3 lower panel). These results demonstrated that
overexpression of Aurora-A inhibited the apoptosis induced by
cisplatin.
3.3. Aurora-A enhances ATM/Chk2 to dysregulate the downstream DNA
damage repair molecules
It is well-known that the essential mechanism to kill cancer cells by
chemotherapeutic compounds or IR is to induce cell apoptosis through
irreparable DNA damage. Because ATM/Chk2 and ATR/Chk1 function
at the upstream of signal pathways to participate in DNA repair, weFig. 5.Expression of BRCA1/2 and the effects of BRCA1/2 on cell cycle progression, anchorage-ind
cDNA or shRNA. B. Analysis of BRCA1/2 and Aurora-A after cells were treated with BRCA1/2 s
labeled under each band, and the intensity-based graphs are shown in SFig. 8A–C. C. Quantita
by ﬂow cytometry. Data were collected from three independent assays. D. Anchorage indepen
*P b 0.05, **P b 0.01. Data from three independent experiments were analyzed. E. Xenograft tum
ations of xenograft tumor volumes in mice treated with IR or cisplatin after 38 days.*P b 0.05,ﬁrst detected the expression of ATM/Chk2 and ATR/Chk1 in cells
transfected with Aurora-A cDNA or shRNA by immunoblotting.
Compared with that in control cells, overexpression or silencing of
Aurora-A elevated or reduced the expression of ATM and Chk2, but
suppressed or increased ATR (except in BXPC3 cells) and Chk1
expression (Fig. 3A). The intensity of protein bands is labeled
under each band, and the intensity-based graph is shown in SFig. 7B.
We further tested other downstream DNA repair molecules and
found that the expression of ATR, Chk1, p53, pp53 (Ser15), H2AX,
γH2AX, and RAD51 was suppressed by overexpression of Aurora-
A, but was increased by knockdown of Aurora-A except that ATR
was decreased in BXPC3/Aur-Ai cells, compared with the control
cells (Fig. 3B). The intensity of protein bands is labeled under
each band, and the intensity-based graph is shown in SFig. 7C.
γH2AX is involved in the recruitment of DNA damage repair
factors to the sites of damaged DNA, including DSBs [21] andependent colony formation. A. Detection of BRCA1 and BRCA2 in cells expressing Aurora-A
hRNAs or cDNAs. β-actin was used as a loading control. The intensity of protein bands is
tive analysis of cell cycle distribution. Cells stained with propidium iodide were analyzed
dent growth in soft agar. The colony formation rate of control cell lines were set at 100%.
or volumes burdened in mice injected with MDA-MB-231 and its derivatives. F–G. Alter-
**P b 0.01.
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duced by ultraviolet C irradiation [22]. The localization of γH2AX
foci after DNA damage most likely represents the repair efﬁciency
of damaged DNA [22]. To validate the potential effect of Aurora-A
on DNA repair, we examined the formation of γH2AX foci after IR
and found a negative correlation between Aurora-A and γH2AX
foci (Fig. 3C and SFig. 4). These results demonstrated that Aurora-
A might enhance ATM/Chk2 to dysregulate the DNA damage repair
networks associated with radio- and chemoresistance.
3.4. Inhibition of ATM increases the radio- and chemosensitivity in cells
overexpressing Aurora-A
The above results indicated that Aurora-A might control radio- and
chemoresistance through the upregulation of ATM/Chk2. To conﬁrm
this notion, we treated cells expressing high levels of Aurora-A and
ATM/Chk2 with KU-55933, a potent, selective and ATP-competitive
inhibitor of ATM kinase at the concentration of 20 nM.
As shown in Fig. 4, in response to irradiation, the treatment with
KU-55933 increased the early and late apoptotic cells by 0.4% and
7.2% in MCF-7/Aur-A, by 7.1% and −1.3% in MDA-MB-231, respec-
tively, compared with diluent treatment alone (Fig. 4A–B). Treat-
ment with KU-55933 in addition to cisplatin increased the early
and late apoptotic cells by 2.2% and 4.4% in MCF-7/Aur-A, by 24.6%
and 5.5% in MDA-MB-231 cells compared with diluent and cisplatin
treatment (Fig. 4A–B). These data suggested that the inhibition of
ATM activity enhanced the sensitivity of cancer cells to irradiation
and cisplatin.
To analyze the proteins associatedwithATM-mediatedDNAdamage
repair, we ﬁrst treated breast and ovarian cancer cells overexpressing
Aurora-A/ATM with X-ray (8 Gy) or cisplatin (10 mg/L) separately,
and then treated these cells with the ATM inhibitor KU-55933 along
with cisplatin or IR. As shown in Fig. 4C, the expression of pp53
(Ser15), Chk2, γH2AX (Ser139), and RAD51 were elevated or
unchanged in response to DNA damage. Compared with control cells
treated with DMSO, cells treated with KU-55933, or with KU-55933
+ cisplatin, or with KU-55933 + IR reduced the expression of Chk2,
but increased the phosphorylation of p53 (Ser15). Inhibition of ATM
also reduced the levels of γH2AX (except in MDA-MB-231 cells treated
with KU-55933 + cisplatin) and RAD51 (except in MDA-MB-231 cells
treated with KU-55933 or KU-55933 + cisplatin, and OVCA420/Aur-A
treated with KU-55933) (Fig. 4D), indicating a slight difference of DNA
repair signaling between ATM and Aurora-A. The intensity of protein
bands is labeled under each band, and the intensity-based graphs are
shown in SFig. 7D–E.
These results demonstrated that the inhibition of ATM could dimin-
ish the Aurora-A-mediated radio- and chemoresistance through regula-
tion of the downstream signal molecules in DNA repair pathways.
3.5. BRCA1/2 suppresses Aurora-A to reduce the cell proliferation, cell cycle
progression, in vitro and in vivo tumorigenicity
Aurora-A has been reported to inhibit the expression of BRCA1/2
[15,16] and BRCA1/2 may inversely suppress the activity or expression
of Aurora-A kinase [23,24]. Thus, BRCA1/2 may counteract the function
of Aurora-A to elevate cancer cell sensitivity to treatmentwith radiation
and genotoxic reagents. To validate this hypothesis, we ﬁrst tested the
expression of BRCA1/2 in cells either expressing Aurora-A cDNA or
Aurora-A shRNA. As shown by Western blotting in Fig. 5A, compared
with the control cells, the expression level of BRCA1/2 was down-
regulated in Aurora-A-transfected cells (MCF-7/Aur-A, PANC-1/Aur-A,
and OVCA420/Aur-A), but was elevated in Aurora-A-silenced cells
(MDA-MB-231/Aur-Ai, BXPC3/Aur-Ai, and OVCA429/Aur-Ai). The
intensity of protein bands is labeled under each band, and the
intensity-based graph is shown in SFig. 8A.To further test the negative regulation between Aurora-A and
BRCA1/2, shRNAs or cDNAs of BRCA1/2 were transfected into cells
with high expression of BRCA1/2 or Aurora-A. Compared with the con-
trol cells, silencing of BRCA1/2 expression increased the expression of
Aurora-A, while overexpression of BRCA1/2 reduced the expression of
Aurora-A (Fig. 5B). The intensity of protein bands is labeled under
each band, and the intensity-based graph is shown in SFig. 8B–C.
Next, we examined cell proliferation, cell cycle progression, and
in vitro tumorigenicity in cells transfected with BRCA1/2 cDNAs or
shRNAs. Cell proliferation increased after BRCA1/2 was silenced, while
overexpression of BRCA1/2 reduced the cell growth (SFig. 5A). The
data from cell cycle analysis showed that the knockdown of BRCA1 de-
creased the G0–G1 population, but increased the G2–M population in
MCF-7/BRCA1i cells compared with in MCF-7/Scr cells. No changes in
cell cycle were observed in BRCA2-silenced MCF-7 cells compared
with the control cells (Fig. 5C). However, in comparison with
MDA-MB-231/vector cells, overexpression of BRCA1 or BRCA2 in-
creased the number of cells by 29.9% and 29.0% at G0–G1 phase
and reduced the number of cells by 4.6% and 0.7% at S phase and
by 25.3% and 28.3% at G2–M phase in MDA-MB-231/BRCA1 and
MDA-MB-231/BRCA2 cells, respectively (Fig. 5C).
The soft agar assay showed that silencing of BRCA1 or BRCA2 in-
creased the number of colonies formed by MCF-7/BRCA1i and MCF-7/
BRCA2i cells, while overexpression of BRCA1 or BRCA2 decreased the
number of colonies formed by MDA-MB-231/BRCA1 and MDA-MB-
231/BRCA2 cells (Fig. 5D and SFig. 5B). Similar results were obtained
from ovarian and pancreatic cancer cell lines (data not present). To
strengthen the aforementioned results, we performed animal assays
by using MDA-MB-231 cells and their derivatives. Mice burdened with
tumors at 38 days post injection were treated with or without IR or
cisplatin as described inMM section.We ﬁrst found that overexpression
of Aurora-A or knockdown of BRCA1/2 decreased tumor growth
(Fig. 5E). Treatment of cells expressing Aur-Ai or BRCA1/2 with IR or
cisplatin markedly reduced the tumor growth, compared with the
tumors formed by cells expressing vector or Scr after the same treat-
ments (Fig. 5F–G).
These results suggested that BRCA1/2might counteract the function
of Aurora-A to inversely regulate cell proliferation, cell cycle progres-
sion, in vitro and in vivo tumorigenesis in breast, pancreatic and ovarian
cancer cells, which may subsequently attenuate the radio- and
chemoresistance of cancer cells.
3.6. BRCA1/2 regulate ATM/Chk2 and DNA damage repair signaling to
enhance the radio- and chemosensitivity
To test the effect of BRCA1/2 on DNA damage repair, we ﬁrst
detected the expression of the same molecules tested above. As
shown in Fig. 6A, silencing of BRCA1 increased the expression of ATM
and Chk2 (except in MCF-7/BRCA1i), but had no effect on RAD51,
while silencing of BRCA2 decreased both ATM and RAD51 expression.
However, the expression of p53, pp53 (Ser15) (except in MCF-7/
BRCA1i and MCF-7/BRCA2i), and γH2AX was decreased after
silencing of BRCA1 or BRCA2. Overexpression of BRCA1 decreased
the expression of ATM (except in OVCA429/BRCA1), Chk2 (except
in MDA-MB-231/BRCA1), but the effect on RAD51 was inconsistent.
Overexpression of BRCA2 slightly increased ATM, and RAD51 (ex-
cept in MDA-MB-231/BRCA2), but decreased Chk2, indicating a reg-
ulatory difference between BRCA1 and BRCA2. Overexpression of
BRCA1/2 enhanced the expression of p53, pp53, and γH2AX. These
data suggested that BRCA1/2 might control DNA damage response
through ATM/Chk2. The intensity of protein bands is labeled
under each band, and the intensity-based graph is shown in
SFig. 8D.
To detect the radio- and chemosensitivity, cells were treated
with X-ray (8 Gy) or cisplatin (10 mg/L). In response to IR, the num-
ber of early apoptotic cells was reduced only in MCF-7/BRCA1i cells,
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and MCF-7/BRCA2i cells, compared with MCF-7/Scr cells. The num-
bers of both early and late apoptotic cells were markedly increased
in MDA-MB-231/BRCA1/2 cells compared with MDA-MB-231/vec-
tor cells (Fig. 6B–C, SFig. 5A). In response to cisplatin, the early ap-
optotic cells were increased after BRCA1/2 was silenced in MCF-7
cells, but the late apoptotic cells were remarkably decreased. Both
the early and late apoptotic cells were markedly increased after
the ectopic expression of BRCA1/2 in MDA-MB-231 cells (Fig. 6D–
E, SFig. 5A). To strengthen the above results, we delivered BRCA1/2
cDNAs or shRNAs into OVCA420/Aur-A and OVCA429/Aur-Ai cells, re-
spectively, and treated the resulting cells with X-ray and cisplatin. As
shown in Fig. 6F–G and in SFig. 5B, in response to cisplatin, introduction
of BRCA1/2 in OVCA420/Aur-A cells increased the drug sensitivity with
decreased IC50 (b20 mg/L), compared to control cells treated with
vector or scrambled shRNA. Silencing of BRCA1/2 increased the
drug resistance with increased IC50 (N20 mg/L). Treatment of cells
with IR increased or decreased apoptosis in cells transfected with
BRCA1/2 cDNAs or BRCA1/2 shRNAs (data not shown). These results
suggested that Aurora-A and BRCA1/2 might bemutually suppressed
to modulate cancer cell response to radio- and chemotherapy
through dysregulation of ATM/Chk2-mediated DNA repair networks.
4. Discussion
It is well-known that the resistance of cancer cells to radio- and
chemotherapy is usually associated with the dysregulated DNA dam-
age repair response. The effector proteins involved in the DNA dam-
age response are either directly phosphorylated by ATM/ATR or by
the checkpoint kinases Chk2 and Chk1 that act at the downstream
of ATM and ATR [25]. A recent study revealed that Aurora-A modu-
lates the activation of PLK1 to impair Chk1, resulting in the inhibition
of RAD51 and the decreased HR [17], while the phosphorylation of
p53 at serine 15 is associated with ATM in response to IR [26]. In
this study, we performed a comprehensive study of Aurora-A in six
cell lines from three different cancer types. We found, by both
in vitro and in vivo experiments, that Aurora-A and BRCA1/2 inverse-
ly control cancer cell sensitivity to IR and cisplatin through the ATM/
Chk2-mediated DNA damage repair networks, although a few incon-
sistent results including those of cell cycle distribution were seen in
different cell lines due to their genetic diversiﬁcation. Our results
showed that the overexpression of Aurora-A suppressed the expres-
sion of ATR, Chk1, p53, pp53 (Ser15), H2AX, γH2AX (Ser139), and
RAD51, but enhances the levels of ATM and Chk2 in most of the cell
lines (Fig. 3A–C). Furthermore, we showed that the inactivation of
ATM by the speciﬁc inhibitor KU-55933 downregulated Chk2, but
upregulated pp53 to reduce the radio- and chemoresistance
(Fig. 4), indicating that the abnormal signaling of ATM/Chk2/p53
may play a critical role in Aurora-A-induced cancer cell radio- and
chemoresistance, which is partially supported by the results from
glioma cells [27].
H2AX can be phosphorylated as γH2AX by ATM and forms foci to
be recruited for DNA repair along with RAD 51 upon DNA damage
[28,29]. We showed that Aurora-A decreased the focus formation of
γH2AX in response to IR, indicating that Aurora-A may dysregulate
DNA repair through the γH2AX-mediated homologous recombina-
tion. We found that the expression of γH2AX and RAD51 was not in-
creased in cells treated with KU-555933 alone or with KU-55933
plus cisplatin or IR compared with cells treated with DMSO. This
may indicate that the downregulation of γH2AX and RAD51 by
Aurora-A may be independent of ATM-Chk2 signaling and notFig. 6. Effects of BRCA1/2 on the DNA repair networks and on the cell sensitivity to IR and cis
BRCA1/2 shRNAs or cDNAs. The intensity of protein bands is labeled under each band, and the
cells (as indicated) in breast cancer cells treatedwith X-ray at 8 Gy. D and E. Percentage of early a
for 48 h. Error bars= 95% CIs. F and G. Sensitivity to cisplatin tested as cell viability byMTT afteessential to Aurora-A-induced radio- and chemoresistance, although
detailed studies may be needed to validate this notion.
Studies have shown that BRCA1 acts in multiple aspects to repair
the DSBs via HR [30], and is required for the phosphorylation of p53
(Ser15) and a G1/S arrest following IR-induced DNA damage [31].
BRCA2 is associated with the G1/S and the G2/M checkpoints [32]
and also performs core functions in HR [33]. The BRC repeats of
BRCA2 modulate the DNA-binding selectivity of RAD51, which
coats ssDNA of the damaged DNA and initiates strand exchange be-
tween the paired DNAmolecules [33]. In this study, we showed that
the effects of Aurora-A on cell proliferation, cell cycle progression,
anchorage-independent colony formation, and cancer cell resis-
tance to IR and cisplatin treatment could be mimicked or reversed
by the silencing or overexpression of BRCA1/2. Moreover, Aurora-
A and BRCA1/2 inversely controlled the DNA damage responsive
proteins including ATM/Chk2, ATR/Chk1, p53, RAD51, and the phos-
phorylation of p53 (Ser15), γH2AX (Ser139). Thus, based on the lit-
erature and our results, the cancer cell radio- and chemoresistance
driven by Aurora-A may be caused by insufﬁcient cell cycle check-
point controls and deﬁcient DNA damage repair networks that are
counteractively managed by the functional BRCA1/2 molecules.
Aurora-A is known to regulate BRCA1 through phosphorylation
[15], but whether it also negatively regulates BRCA2 through phos-
phorylation has not yet been reported. We have recently reported
that Aurora-A and BRCA2 are mutually suppressed to control ovarian
cancer tumorigenesis through regulation of RAS-associated genetic
instability [19]. Overexpression of Aurora-A inhibits BRCA2 expres-
sion and induces malignant transformation of immortalized human
ovarian surface epithelial cells, while silencing of Aurora-A in RAS-
transformed cells enhances BRCA2 expression and reduces tumor
growth [19]. Introduction of BRCA2 into RAS-transformed cells di-
minished Aurora-A expression and tumor growth [19]. Although
co-localization of Aurora-A and BRCA2 has been found in the
midbody of late mitotic cells during cytokinesis, the essential regula-
tion between Aurora-A and BRCA2 has not been deﬁned [19]. As
others and we previously reported, both Aurora-A and BRCA2 could
be regulated through proteolysis-mediated degradation [19,34,35].
Thus, we presume that Aurora-A may regulate BRCA2 through phos-
phorylation and proteasome-mediated degradation, while BRCA1/2
may regulate Aurora-A expression through a feedback proteolysis-
mediated degradation. Nevertheless, more investigations are needed
to decode these speculations.
Taken together, our data suggest that Aurora-A controls radio- and
chemoresistance through the ATM/Chk2-mediated dysregulation of
DNA damage repair networks including pp53, γH2AX, and RAD51,
whereas BRCA1/2 suppress Aurora-A to counteract the Aurora-A-
induced radio- and chemoresistance by remodeling the DNA repair
pathways. However, the molecular mechanism of how BRCA1/2 nega-
tively regulate the expression of Aurora-A still needs further
investigations although this notion has been evidenced or discussed in
the current study as well as in our previous publications [16,24].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.01.019.
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